Screener
Krystal Biotech, Inc. KRYS Q2 2026 earnings
Reported August 3, 2026 · Before market open
Revenue$119.2MMiss by $1.7M
EPS$1.79Beat by $0.09
Revenue estimate$120.9M
EPS estimate$1.70
“VYJUVEK is not only changing the standard of care for DEB patients around the world, it is also giving us the ability to advance high-conviction rare disease programs across the eye, lung, and skin with focus and discipline. We believe the next 12 to 18 months have the potential to mark an important transition for Krystal from a commercial success story to a multi-product genetic medicines company.”
Next report
Nov 2, 2026 (in a month)Revenue estimate$129.1M
EPS estimate$1.91
Valuation & ratios
Valuation
as of 10/02/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Krystal Biotech, Inc. report Q2 2026 earnings?
- Krystal Biotech, Inc. (KRYS) reported Q2 2026 earnings on August 3, 2026 before market open.
- What were Krystal Biotech, Inc.'s Q2 2026 revenue and EPS?
- Krystal Biotech, Inc. reported revenue of $119.2M and eps of $1.79 for Q2 2026.
- Did Krystal Biotech, Inc. beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $120.9M by $1.7M. EPS beat the consensus estimate of $1.70 by $0.09.
- How did Krystal Biotech, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 24.1% from $96.0M a year earlier and eps grew 38.8% from $1.29.
- Where can I find Krystal Biotech, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001711279-26-000058) and the 10-Q periodic report (0001711279-26-000057) directly on SEC EDGAR. The filing index links above go to sec.gov.
